NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company announced that the US Patent Office has issued a Notice of Allowance for a patent covering NurExone's proprietary process for producing exosomes-further validating the uniqueness of the product and securing the right to it.
